1. Seya T., and K. Miyake. 2009. Toll-like receptor.Encyclopedia of Molecular Medicine(Nature Publishing Group) Ed. by T. E. Creighton. John Wiley & Sons, Inc. New York, NY a0004028. www.els.net.
  2. Watanabe, T., K. Ito, M. Matsumoto, T. Seya, K. Hatakeyama, S. Nishikawa, T. Hasegawa, and K. Fukuda. 2009. Isolation and Characterization of RNA aptamers specific for the human Toll-like receptor 3 ectodomain. Viva Origino. 37: 10-18.
  3. Oshiumi, H., M. Matsumoto, S. Hatakeyama, and T. Seya. 2009. Riplet/RNF135, a RING-finger protein, ubiquitinates RIG-I to promote interferon-b induction during the early phase of viral infection. J. Biol. Chem. 284: 807-817.
  4. Wu, J. D., C. L. Atteridge, X. J. Wang, T. Seya, and S. R. Plymate. 2009. Obstructing shedding of the immune stimulatory MHC class I chain-related gene B prevents tumor formation. Clin. Cancer Res. 15: 632-640.
  5. Oshiumi, H., Y. Suzuki, M. Matsumoto, and T. Seya. 2009. Regulator of Complement Activation (RCA) gene cluster in Xenopus tropicalis. Immunogenetics 61:371-384.
  6. Akao, Y., T. Ebihara, H. Masuda, Y. Saeki, K. Hazeki, O. Hazeki, M. Matsumoto, and T. Seya. 2009. Enhancement of antitumor natural killer cell activation by orally administered Spirulina extract in mice. Cancer Sci. 100:1494-1501.
  7. Fujimoto, Y., M. Hashimoto, M. Furuyashiki, M. Katsumoto, T. Seya, Y. Suda, andK. Fukase. 2009. Innate Immunostimulatory lipopepitdes of Staphylococcus aureus as TLR2 ligands; Prediction with mRNA expression, chemical synthesis and immunostimulatory activities.Chem. Biol. Chem. 10: 2311-2315.
  8. Yasukawa, K., H. Oshiumi, M. Takeda, Y. Yanagi, T. Seya, S. Kawabata and T. Koshiba. 2009. Mitofusin 2, a mitochondrial fusion mediator, acts as a negative regulator for mitochondrial antiviral signaling. Science Signaling. 2(84): ra47.
  9. Kodama, K., M. Higashiyama, K. Takami, K. Oda, J. Okami, J. Maeda, T. Akazawa, M. Matsumoto, T. Seya, M. Wada, A. Hayashi, and K. Toyoshima. 2009. Innate immune therapy with a BCG cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study. Surgery Today. 39: 194-200.
  10. Takaki, H., H. Oshiumi, T. Kawanishi, M. Sasai, M. Matsumoto, and T. Seya. 2009. Cytoplasmic oligomerized TICAM-1 recruits nuclear BS69 to enhance type I interferon induction.Eur. J. Immunol.39: 3469-3476.
  11. Iwakiri. D.,L. Zhou, M. Samanta, M. Matsumoto, T. Ebihara, T. Seya, S. Imai, M. Fujieda, K. Kawa, and K. Takada. 2009. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J. Exp. Med. 206: 2091-2099.
  12. Seya, T., M. Matsumoto, T. Ebihara, and H. Oshiumi. 2009. Functional evolution of the TICAM-1 (TRIF) pathway for extrinsic RNA sensing. Immunol. Rev. 227: 44-53 (review).
  13. Seya, T., and M. Matsumoto. 2009. The extrinsic RNA-sensing pathway for adjuvant immunotherapy for cancer. Cancer Immunol. Immunother. 58:1175- 1184 (review).
  14. Ebihara, T. M. Matsumoto, and T. Seya. 2009. Dendritic cell/NK cell interaction in RNA virus infection. Curr. Immunol. Rev. 5: 200-207 (review).